The good news for Geron's investors? Now that the Menlo Park, California-based company has terminated development of GRN1005 and plans to lay off 64 of its 107 employees, it has enough cash on hand to fund its operations for two or three years.
The good news for Geron's investors? Now that the Menlo Park, California-based company has terminated development of GRN1005 and plans to lay off 64 of its 107 employees, it has enough cash on hand to fund its operations for two or three years.
The bad news? Geron has $90 million in investor cash to spend on its one remaining drug candidate: the telomerase...
The company announced positive Phase III data in previously treated colorectal cancer for zanzalintinib and it could see sales of more than $1bn in that indication.
The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.
Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.
The company announced positive Phase III data in previously treated colorectal cancer for zanzalintinib and it could see sales of more than $1bn in that indication.
